…[ie] deuterated psilocybin analog has a duration of effect that is half is long as psilocybin, and a duration onset that is twice as fast.

…[research pipeline seeking & developing] drugs with less variability [with goals such as] a faster onset time and better brain penetration that maintain the therapeutic properties of psilocybin and deliver them within a shorter time period.

Original Article (Forbes):
Pre-clinical data shows cybin’s novel analog could have advantages over psilocybin
Artwork Fair Use: Universidad Europea del Atlántico